Journal Information
Vol. 88. Issue 2.
Pages 191-192 (April - June 2023)
Share
Share
Download PDF
More article options
Vol. 88. Issue 2.
Pages 191-192 (April - June 2023)
Letter to the Editor
Full text access
Emergency management of hepatic encephalopathy
Manejo de urgencia de encefalopatía hepática
Visits
1785
K.L. Rodriguez-Peralta
Corresponding author
luana040402@gmail.com

Corresponding author at. Universidad Privada San Juan Bautista, Lima, Peru.
, J.A. Santiago-Ferrer
Gastroenterología, Universidad Privada San Juan Bautista, Lima, Peru
Related content
J.A. Velarde-Ruiz Velasco
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
Dear Editors,

After reading and analyzing the article “Evaluation and management of emergencies in the patient with cirrhosis”, we wish to share our thoughts and comments on the theme. Hepatic encephalopathy (HE) is one of the main complications of cirrhosis. It consists of brain dysfunction, as a consequence of liver failure, and produces alterations at the subclinical level that can lead to coma. Thus, it is considered a medical emergency and should be treated immediately.1

Nonabsorbable disaccharides, such as lactulose and lactitol, are the first-line treatment. The article does not precisely state under which circumstances they should be used. Their administration depends on the grade of HE. In cases of grade I and potential grade II, oral administration is indicated, whereas in grades II, III, and IV, administration can be carried out through a nasogastric tube or by means of an enema, if the patient is unable to receive oral administration.2

Nonabsorbable antibiotics are of great use as an alternative to nonabsorbable disaccharides, and include neomycin, metronidazol, and rifaximin. Of those three, rifaximin is the most important, due to its current approval by the Food and Drug Administration. However, demonstrating its efficacy as adjuvant therapy is still greatly relevant. In addition, the study by Sharma et al. reinforces the information of the article. Those authors conducted a double-blind randomized trial, in which 120 patients with HE received only lactulose or lactulose plus rifaximin (1,200 mg/day). The patients that received the combined treatment had better HE resolution, as well as a statistically significant decrease in the number of days of hospital stay (5.8 + 3.4 vs 8.2 + 4.6 days, p 1/4 0.001), compared with the patients that received only lactulose.3

Intravenous L-ornithine L-aspartate (LOLA) can be added in patients that do not respond to conventional treatment. In a double-blind randomized trial, a higher improvement rate in grade of HE (92.5% vs 66%, P < .001), shorter recovery time (2.70 ± 0.46 vs 3.00 ± 0.87 days, P = .03), and a lower mortality rate (16.4% vs 41.8%, P = .001) were reported in patients that received the combination of LOLA, lactulose, and rifaximin, compared with patients that received placebo, lactulose, and rifaximin.4

Including the complementary administration of nonabsorbable disaccharides, according to HE classification, is suggested as a better approach. Likewise, the search for and/or carrying out of clinical trials that evaluate the efficacy of the different treatment combinations for HE is considered opportune, favoring rapid patient recovery and a reduced mortality rate.

Financial disclosure

No financial support was received in relation to this study/article.

Conflict of interest

The authors declare that there is no conflict of interest.

References
[1]
J.A. Velarde-Ruiz Velasco, E.S. García-Jiménez, J.M. Aldana-Ledesma, et al.
Evaluación y manejo de emergencias en el paciente con cirrosis.
Rev Gastroenterol Mex., 87 (2022), pp. 198-215
[2]
J.R. Bravo-Coello, V.A. Pacheco-Moreira, M.C. Monar-Goyes, et al.
Manejo clínico y terapéutico en pacientes con cirrosis hepática.
Dom Cien., 7 (2021), pp. 90-112
[3]
J.P. Reinert, K. Burnham.
Non-lactulose medication therapies for the management of hepatic encephalopathy: a literature review.
J Pharm Pract., 34 (2021), pp. 922-923
[4]
A. Jain, B.C. Sharma, B. Mahajan, et al.
L-ornithine L-aspartate in acute treatment of severe hepatic encephalopathy: a double-blind randomized controlled trial.
Hepatology., 75 (2022), pp. 1194-1203

Please cite this article as: Rodriguez-Peralta KL, Santiago-Ferrer JA. Manejo de urgencia de encefalopatía hepática. Rev Gastroenterol Méx. 2023;88:191–192.

Copyright © 2023. Asociación Mexicana de Gastroenterología
Idiomas
Revista de Gastroenterología de México
Article options
Tools
es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.